136 related articles for article (PubMed ID: 8824353)
1. A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.
Geyer JR; Balis FM; Krailo MD; Heideman R; Broxson E; Sato JK; Poplack D; Bleyer WA
Invest New Drugs; 1996; 13(4):337-42. PubMed ID: 8824353
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
[TBL] [Abstract][Full Text] [Related]
4. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas.
Marina NM; Poquette CA; Cain AM; Jones D; Pratt CB; Meyer WH
J Pediatr Hematol Oncol; 2000; 22(2):112-8. PubMed ID: 10779023
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide in pediatric solid tumors.
Carli M; Passone E; Perilongo G; Bisogno G
Oncology; 2003; 65 Suppl 2():99-104. PubMed ID: 14586158
[TBL] [Abstract][Full Text] [Related]
6. High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study.
Lafay-Cousin L; Hartmann ; Plouvier P; Méchinaud F; Boutard P; Oberlin O
Bone Marrow Transplant; 2000 Sep; 26(6):627-32. PubMed ID: 11035368
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors.
Lucidarme N; Valteau-Couanet D; Oberlin O; Couanet D; Kalifa C; Beaujean F; Lapierre V; Hartmann O
Bone Marrow Transplant; 1998 Sep; 22(6):535-40. PubMed ID: 9758339
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
[TBL] [Abstract][Full Text] [Related]
9. A review of the past, present, and future clinical trials from the Children's Cancer Group.
Bergeron S
J Pediatr Oncol Nurs; 1998 Apr; 15(2):98-102. PubMed ID: 9597819
[No Abstract] [Full Text] [Related]
10. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Cosetti M; Wexler LH; Calleja E; Trippett T; LaQuaglia M; Huvos AG; Gerald W; Healey JH; Meyers PA; Gorlick R
J Pediatr Hematol Oncol; 2002 Feb; 24(2):101-5. PubMed ID: 11990694
[TBL] [Abstract][Full Text] [Related]
11. High-dose Thiotepa as Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation for High-risk Ewing Family Tumors: Single-institution Experience.
Jahnukainen K; Kallio P; Koivusalo A; Saarinen-Pihkala UM
J Pediatr Hematol Oncol; 2015 Oct; 37(7):536-42. PubMed ID: 26207773
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
[TBL] [Abstract][Full Text] [Related]
13. The value of adjuvant chemotherapy in the management of sarcomas in children.
Donaldson SS
Cancer; 1985 May; 55(9 Suppl):2184-97. PubMed ID: 3884137
[TBL] [Abstract][Full Text] [Related]
14. Sarcomas of the hand and foot: analysis of local control and functional result with combined modality therapy in extremity preservation.
Johnstone PA; Wexler LH; Venzon DJ; Jacobson J; Yang JC; Horowitz ME; DeLaney TF
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):735-45. PubMed ID: 8040019
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Bond M; Bernstein ML; Pappo A; Schultz KR; Krailo M; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2008 Feb; 50(2):254-8. PubMed ID: 17262795
[TBL] [Abstract][Full Text] [Related]
16. Children's Oncology Group's 2023 blueprint for research: Bone tumors.
Reed DR; Grohar P; Rubin E; Binitie O; Krailo M; Davis J; DuBois SG; Janeway KA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30583. PubMed ID: 37501549
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
18. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
19. Therapy associated changes in childhood tumors.
Lowichik A; Zhou H; Pysher TJ; Smith L; Lemons R; Coffin CM
Adv Anat Pathol; 2000 Nov; 7(6):341-59. PubMed ID: 11078058
[TBL] [Abstract][Full Text] [Related]
20. Advances in the pharmacology of cancer chemotherapy.
Smith SD
Pediatr Clin North Am; 1981 Feb; 28(1):145-60. PubMed ID: 6259577
[No Abstract] [Full Text] [Related]
[Next] [New Search]
